Why the study?
Thrombosis plays a critical role in vascular diseases, but little is known about the diagnostic accuracy of the cut-off level for PF1+2 elevations.
Can prothrombin fragment 1+2 (PF1+2) measurement be utilized as a diagnostic and prognostic biomarker for thrombosis in patients with vascular disorders?
Can prothrombin fragment 1+2 (PF1+2) measurement be utilized as a diagnostic and prognostic biomarker for thrombosis in patients with vascular disorders?
Answers are grounded in this paper and cite their sources.
PF1+2 is a promising biomarker for detecting in vivo thrombin generation and hypercoagulable states across various vascular diseases, though standardized diagnostic cut-offs are still needed.
One potential useful tool for diagnosing thrombosis is the prothrombin fragment 1+2 (PF1+2) that is generated when factor Xa cleaves prothrombin. The realisation that thrombosis plays a critical role in the genesis of vascular diseases has generated growing interest in the relationship between PF1+2 and clinical characteristics. The goal of the current review is to stimulate more translational and clinical research on this topic by offering an up-to-date update on the studies investigating whether PF1+2 measurements may be utilised as a diagnostic technique for vascular disorders. Hence; we performed a comprehensive review to describe the reports of elevated PF1+2 levels in venous thromboembolism, inflammation, cancer, sepsis, acute coronary syndromes, stroke, atrial fibrillation, rheumatoid arthritis, liver and kidney disorders, and in the post-operative period. Systematic searches in the English language were conducted in the Pubmed database. It may also be useful in assessing the efficacy of different treatments, in addition to its potential prognostic and diagnostic value. Although, elevations occur in the presence of overt thrombosis as well as the hypercoagulable state. However, to date, little is known about the diagnostic accuracy of the cut-off level to be employed for the definition of elevations. Therefore, additional research is necessary to develop a non-invasive technique for the evaluation of PF1+2 levels in the laboratory in order to predict prognosis in a variety of vascular disorders. This review comprises the clinical application of PF1+2 in hemorrhagic and cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Bharti et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: